NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

(2023) Masahiro Tsuboi et al.   NEW ENGLAND JOURNAL OF MEDICINE

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

(2023) Makoto Nishio et al.   Clinical Lung Cancer

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

(2022) Piyada Sitthideatphaiboon et al.   Scientific Reports

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer

(2022) Hirofumi Takahashi et al.   CANCER SCIENCE

A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

(2022) David Heredia et al.   LUNG CANCER

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib

(2021) Xiao-ru Zhou et al.   ACTA PHARMACOLOGICA SINICA

A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors

(2021) Francesca Iommelli et al.   Cancers

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

(2021) Misako Nagasaka et al.   Clinical Lung Cancer

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

(2021) Hirohito Tada et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

(2021) Si-Yang Liu et al.   Nature Communications

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

(2021) Yi-Long Wu et al.   Journal of Thoracic Oncology

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

(2020) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

(2020) Kadoaki Ohashi et al.   LUNG CANCER

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

(2019) Gillianne G.Y. Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

(2019) Yukio Hosomi et al.   JOURNAL OF CLINICAL ONCOLOGY

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies

(2019) Xuan Zhu et al.   Frontiers in Oncology

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

(2018) Henning Reis et al.   Clinical Lung Cancer

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

(2018) Siddhartha Devarakonda et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

(2018) Youjin Kim et al.   Journal of Thoracic Oncology

Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010

(2018) Jiro Okami et al.   Journal of Thoracic Oncology

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo

(2013) Mian Xie et al.   EUROPEAN JOURNAL OF CANCER

CREBBP mutations in relapsed acute lymphoblastic leukaemia

(2011) Charles G. Mullighan et al.   NATURE

Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis

(2010) Elisa Benedettini et al.   AMERICAN JOURNAL OF PATHOLOGY

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation

(2010) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY